Introduction
============

Connexins are a family of integral transmembrane proteins (indicated by Cx followed by their molecular weight in kDa, e.g., hCx26 for human connexin 26, encoded by the *GJB2* gene) which form hexameric plasma membrane structures known as "connexons." A connexon may function as a regular plasma membrane channel, termed "hemichannel," or dock head-to head with another connexon from an opposing cell and self-assemble into a gap junction intercellular channel ([@B46]).

Partial high-resolution crystal structures have been determined only for hCx26 ([@B44]) and sheep Cx46/50 ([@B50]). However, due to the relatively high sequence similarity across the family, all connexin proteins are thought to share a topology similar to that of hCx26 or Cx46/50, which comprise 4 transmembrane helices (TM1-4) connected by 2 extracellular loops (EC1, EC2) and 1 intracellular loop (ICL). An N-terminal helix (NTH) domain folds into the cytoplasmic channel vestibule and is connected to the pore-lining TM1 helix via a short linker. The ICL, connecting TM2--TM3, and the cytoplasmic C-terminal domain (CTD) were not resolved ([@B44]; [@B50]). The CTD, which is considered to be unstructured, is the most diverse domain and its length is different in each connexin isoform. The fairly conserved sequences of EC1 and EC2 suggest the extracellular vestibule of all hemichannels has a relatively rigid three-dimensional (3D) structure. In MD simulations lasting ∼100 ns, it appears to be the stiffest part of the hemichannel ([@B78]) due to the presence of six conserved cysteine residues, three in each loop, forming intramolecular disulfide bonds between EC1 and EC2 ([@B44]; [@B50]).

In a hCx26 gap junction channel, the extracellular docking interface of each connexon comprises hydrogen bonding between Asn54 of EC1 and the main-chain amide of Leu56 in the opposite protomer, and a pair of Gln57 in two diagonally opposite protomers (these residues are highly conserved among connexins). Also EC2 contributes to the connexon-connexon interaction with a complex network of hydrogen bonds and salt bridges mediated by Lys168, Asn176, Thr177 and Asp179 in two opposite protomers ([@B44]).

Accurate control of undocked hemichannel gating is crucial for cell survival and organism health. Indeed, "leaky" or more active mutant hemichannels result in cell death when expressed in model cells ([@B1]; [@B27]; [@B43]; [@B68]; [@B24], [@B23]; [@B42]; [@B61], [@B63], [@B60]; [@B70]; [@B74]; [@B16]; [@B39]; [@B49]; [@B56]; [@B10]; [@B51]; [@B69]; [@B77]; [@B71]; [@B62]; [@B53]; [@B73]; [@B66]); reviewed in [@B57], [@B40], and [@B67].

Recently, a human-derived single-chain fragment variable (scFv) fragment constant (Fc) antibody (scFv-Fc) named abEC1.1 ([@B55]) was shown to inhibit both wild type (wt) and hyperactive pathological hCx26 hemichannels ([@B73]). The crystal structure of the scFv domain was solved (Protein Data Base accession code 5WYM) and some of the residues that are critical for its binding to the extracellular domain of hCx26 hemichannels were identified.

The goals of the present study were to characterize further the biophysical properties of this antibody, particularly its selectivity for connexin hemichannels, and to assay its *in vitro* stability, which is a pre-requisite for future *in vivo* delivery to animal models of disease.

Materials and Methods {#s1}
=====================

Antibody Production
-------------------

The gene encoding the antibody scFv domain was cloned into a pFUSE-Fc expression vector (Cat. No. pfuse-hg1fc2, Invivogen, Hong Kong) to generate abEC1.1 as a diabody-Fc fusion protein ([@B72]) which comprises the entire Fc domain of human immunoglobulin G1 (IgG1) ([@B65]; [@B15]; [@B29]). In addition, the pFUSE-Fc expression vector was modified to generate a variant of the antibody with a murine Fc (abEC1.1m). For antibody production, a FreeStyle^TM^ 293-F cell line (Thermo Fisher Scientific, Cat. No. R79007), maintained in Freestyle 293 Expression Medium (Thermo Fisher Scientific, Cat. No. 12338026), was stably transfected with the abEC1.1 or abEC1.1m expression vector. Expressed antibodies were purified using HiTrap Protein A HP columns (GE Healthcare, Cat. No. 17-0403-03) with the ÄKTApurifier 100 system (GE Healthcare). After purification, the buffer was exchanged to PBS (pH 7.4) and the antibodies were kept in PBS at 4°C.

Size Exclusion Chromatography (SEC)
-----------------------------------

To characterize the *in vitro* stability of abEC1.1 and abEC1.1m by SEC ([@B28]; [@B12]), eppendorf tubes containing 4.2 mg/mL of antibody per tube were incubated at 4°C, room temperature (∼22°C), 37°C and 42°C for 3, 5, 7 and 16 days. At each time point, 20 μL of solution were loaded into a Nanofilm SEC-250 column (Sepax Technologies, Inc., DW, United States) and processed at flow-rates of 0.5 mL/min using a 1290 Infinity II liquid chromatography system (Agilent Technologies, Santa Clara, CA, United States). Raw data generated by the instrument (optical density, OD, measured at 405 nm vs. retention time) were normalized to the peak of each chromatogram and plotted using OriginPro 2017 software (OriginLab, Northampton, MA, United States).

Construction of Connexin-Venus Transfection Vectors
---------------------------------------------------

The coding regions of wt *homo sapience* connexin genes^[1](#fn01){ref-type="fn"}^ were synthesized (by Shanghai Sangon Biological Engineering Technology & Services Co., Ltd.) without stop codon and subcloned into a pcDNA3.1(+) mammalian expression vector (Cat. No. V79020, Thermo Fisher Scientific) that had been previously modified for C-terminal fusion of connexin genes with Venus, a circularly permuted mutant of the yellow fluorescent protein (YFP) ([@B8]). After transformation into *Escherichia coli* (TOP10, Cat. No. C404010, Thermo Fisher Scientific), miniplasmid preparation and restriction enzyme analysis were performed to identify positive clones. To verify that PCR amplification did not introduce unwanted mutations, all constructs were sequenced (by Eurofins Genomics S.r.l., Milan, Italy) using standard primers complementary to the plasmid common regions of the constructs, adjacent to the target open reading frames (ORF). Both orientations were sequenced when sequencing was insufficiently reliable as a consequence of the length of the ORF. The primers sequences used for this purpose were:

T7: 5′-TAATACGACTCATAGGG;

myc-ddk-rev: 5′-TGCCAGATCCTCTTCTGAGATGAG.

Patch Clamp Electrical Measurements
-----------------------------------

Communication--incompetent HeLa DH cells (Cat. No. 96112022, Sigma-Aldrich/Merck, Milan, Italy) were seeded onto round glass coverslip (Cat. No. FIS\#12-542A, Thermo Fisher Scientific) and maintained in Dulbecco's modified Eagle's medium (DMEM, Cat. No. 41965039, Thermo Fisher Scientific) containing 10% (v/v) fetal bovine serum (FBS, Cat. No. 10270-106, Gibco-Invitrogen) and 1% penicillin/streptomycin (Cat. No. 15070-063, Gibco-Invitrogen). Twenty four hours after plating, the Lipofectamine 3000 transfection reagent (Cat. No. L3000-015, Thermo Fisher Scientific) was used to transiently transfect HeLa DH cells at 25-30% confluence with one of the connexin-Venus plasmids.

For patch clamp recordings, a double stage vertical puller (PP-830, Narishige) or horizontal laser-based puller (P-2000, Sutter Instrument) were used to fabricate patch pipettes from glass capillaries (G85150T-4, Harvard Apparatus, Edenbridge, United Kingdom). Pipettes were filled with a potassium aspartate-based intracellular solution (ICS~KAsp~) containing (in mM): 115 KAsp, 10 NaCl, 10 KCl, 1 MgCl~2~, 10 HEPES, 1 CaCl~2~ and 4 BAPTA tetrapotassium salt (pH 7.2, 311 mOsm) and filtered through 0.22-mm pores (Millipore). Twenty four hours after transfection, glass coverslips with adherent cells were transferred to the stage of an upright fluorescence microscope (BX51, Olympus) equipped with differential interference contrast (DIC) optics. Cells were continuously superfused at 2 ml/min at 20--23°C with a sodium chloride-based extracellular solution (ECS~NaCl~) containing a reduced (0.2 mM) Ca^2+^ concentration (\[Ca^2+^\]~e~) and (in mM): 140 NaCl, 5 KCl, 10 HEPES, 2 sodium pyruvate, 4 tetraethylammonium chloride (TEA-Cl), 1 MgCl~2~, 4 CsCl and 5 glucose (pH 7.4, 323 mOsm). Filled patch pipettes had resistances of 4--6 MΩ when immersed in ECS~NaCl~.

Hemichannel currents were assayed in ECS~NaCl~ while keeping cells near their zero-current potential (between -20 and 0 mV) under whole cell patch clamp recording conditions. Cells were transiently depolarized to +40 mV for 20 s followed by a ramp down -40 or -60 mV and subsequently held at this negative potential for up to 1 min before stepping back to the zero-current potential. The ramp from positive to negative potentials was preferred to a step to minimize stress to the plasma membrane. To estimate plasma membrane leak currents, connexin hemichannels were blocked by adding either CaCl~2~ (2 mM) or ZnCl~2~ (100 μM) to the superfusion medium ([@B73]).

For antibody application, the opening of a glass micropipette connected to a pneumatic pico-pump (PV820, World Precision Instruments Inc., Sarasota, FL, United States) and filled with the ECS~NaCl~ extracellular solution supplemented with abEC1.1 (952 nM) was positioned near the patched cell. During antibody delivery, the superfusion was stopped.

Negative control experiments were performed in HeLa-Panx1-YFP cells ([@B75]) grown in DMEM with 10% FBS, containing G418 (Cat. No. 4727878001, Sigma-Aldrich/Merck) at a final concentration of 1 μg/mL at 37°C in an incubator supplemented with 5% CO~2~. Pannexin currents were inhibited using the following compounds, all from Sigma-Aldrich/Merck: p-(Dipropylsulfamoyl)benzoic acid (probenecid, Cat. No. P-8761), 3β-Hydroxy-11-oxoolean-12-en-30-oic acid 3-hemisuccinate (carbenoxolone, CBX, Cat. No. C4790), 4,4-Diisothiocyanatostilbene-2,2-disulfonic acid (DIDS, D3514) and Fast Green FCF (Cat. No. F7252-5G).

Dye Uptake Assay
----------------

HeLa DH cells expressing the connexin of interest were imaged in an upright fluorescence microscope (Bergamo II, Thorlabs Inc., Thorlabs Inc., Newton, NJ, United States) using a 25× water immersion objective (XLPLN25XWMP2, 1.05 N.A., Olympus Corporation, Tokyo, Japan) and a programmable illumination system (pE-4000, CoolLED Ltd., Andover, United Kingdom) coupled to the epifluorescence port of the microscope via 474/24 nm bandpass filter (Semrock, Rochester, NY, United States) and dichroic beamsplitter (410/504/582/669 nm BrightLine quad-edge, Semrock). Fluorescence emission was filtered through a 525/39 nm bandpass filter (Semrock) to form images on the sensor of a scientific CCD camera (1501M-USB-TE, Thorlabs). HeLa DH transfectants were maintained in a divalent-free extracellular medium (ECM) containing (in mM): 140 NaCl, 5 KCl, 10 HEPES, 2 sodium pyruvate, and 5 glucose (pH 7.4). Five non-overlapping fields of view were rapidly imaged under fixed illumination and recording conditions (time *t*~0~) using a precision programmable motorized stage (HLD117NN, Prior Scientific Instruments Ltd., Cambridge, United Kingdom). Thereafter, cells were switched to ECM supplemented with 2 mM Lucifer Yellow (CH dilithium salt, Sigma-Aldrich/Merck, Cat. No. L0259) to promote dye uptake ([@B22]; [@B59]). After 30 min of incubation (time *t*~30~), cells were washed three times with ECM supplemented with 2 mM CaCl~2~ (ECM~Ca~) in order to remove dye molecules bound to the outer plasma membrane leaflet and to limit dye escape from cell cytoplasm through open hemichannels. Thereafter, a new set of 5 images were rapidly acquired from the same fields of view. For off-line image processing, regions of interest (ROIs) were drawn over individual cells and ROI average fluorescence intensities were computed. To test antibody efficacy, batches of cells which had been pre-incubated for 30 min in ECM supplemented with abEC1.1 (952 nM) were imaged as explained above. Cells transfected with an empty pcDNA3.1(+) vector (mock transfected) were used as controls for aspecific dye uptake effects. The distributions of fluorescence values, sampled before and after Lucifer Yellow application, were compared statistically using the Mann--Whitney *U* test ([@B47]).

Molecular Modeling and Dynamics
-------------------------------

The abEC1.1 model was derived by homology from two different templates, one for the scFv domain and the other for the Fc domain, which were interconnected by a linker using the Swiss Model website ([@B11]). The scFv domain was then docked to the extracellular domain of a published model of hCx26 hemichannel embedded in the plasma membrane ([@B78]) using the ClusPro 2.0 server ([@B18]), and the antibody docking mode ([@B14]). Among the 50 docking configurations generated by the software, we selected the only one in which the 3 complementarity determining regions (CDRs) of the abEC1.1 heavy chain faced the EC1 loop of hCx26. Configuration stability was tested by performing a MD simulation using the Gromacs 4 package ([@B54]) and the Amber03 force field ([@B26]). Specifically, the atomistic model system, containing the hCx26 hemichannel inserted in a phospholipid bilayer and the docked antibody, underwent a short energy minimization in vacuum and was subsequently solvated with full atom TIP3P water, containing Cl^-^ and K^+^ ions at a concentration of ∼0.15 M in order to mimic a physiological ionic strength. After solvation, the total number of atoms was around 2.53 × 10^5^. We then performed an equilibrium MD simulation under periodic boundary conditions at constant pressure for 150 ns and analyzed the last 10 ns after equilibration. Temperature *T* and pressure *P* were kept constant, at 300 K and 1 atm, respectively, using the Berendsen thermostat and barostat ([@B9]). Fast smooth Particle--Mesh Ewald summation ([@B21]) was used for long--range electrostatic interactions, with a cut off of 1.0 nm for the direct interactions.

Results
=======

*In silico* Analysis of abEC1.1 Interaction With the Extracellular Domain of the hCx26 Hemichannel
--------------------------------------------------------------------------------------------------

Starting from the equilibrated configuration of two abEC1.1 antibodies simultaneously docked to a hCx26 hemichannel ([@B73]) ([Figure 1](#F1){ref-type="fig"}), we analyzed the last 10 ns of the MD simulation (see section "Materials and Methods") and searched for antibody-connexin residue pairs that interacted stably. Interaction probability was measured as the fraction of the simulation time in which the distance between each pair of residues was less than an arbitrarily pre-assigned threshold (2 Å). [Figure 2](#F2){ref-type="fig"} highlights hemichannel residues involved in the interaction with abEC1.1 according to this scoring method. Based on this analysis, we concluded that abEC1.1 binds Asn54, Thr55, Leu56, Gln57, and Pro58 in EC1, as well as Pro175, Asn176 and Thr177 in EC2. Each antibody appears to interact directly with four different protomers (P) of the connexon: the first antibody interacts with P1, P2, P3, and P4; the second with P4, P5, P6, and P1, thus the pair of diametrically opposed protomers, P1 and P4, is able to interact with both binding antibodies at the same time. In other words, the stoichiometry of binding between connexins and antibodies is 6:2, with the two antibodies binding in a symmetric configuration relative to the axis of the channel pore. Details of the interactions are illustrated in [Figure 3](#F3){ref-type="fig"}. Note that only EC1 residues Asn54, Thr55 and Leu56 were present in the bait peptide used to select abEC1.1 out of a phage display library with ∼10^11^ variability ([@B76]). Sequence alignment of all human connexins showed that only hCx26, hCx30 and hCx32 display identical sub-sequences in the predicted binding region ([Table 1](#T1){ref-type="table"}). Therefore we reasoned that the antibody should inhibit also hCx30 and hCx32 hemichannels, whereas it might be less effective or ineffective when applied to hemichannels formed by other connexin isoforms.

![Side view of an antibody pair binding a hCx26 hemichannel. According to our model and to the experimental determination of the stoichiometry of binding, two different antibodies can simultaneously bind the extracellular region of a single connexin hemichannel. Each antibody is a diabody-Fc, i.e., a dimer of two scFv-Fc polypeptides where the heavy chain (HC) and light chain (LC) from one scFv, pair with the complementary domains of a second scFv ([@B52]). In the figure, Fc domains are not shown and each ScFv domain is represented with a different color (green, red, yellow or purple); green-red and yellow-purple represent the two different diabodies, while the connexin hemichannel is shown in blue. For additional structural details, see [@B73].](fphys-10-00392-g001){#F1}

![hCx26 hemichannel residues predicted to interact with abEC1.1. **(A,B)** Schematic representation of a hCx26 hemichannel viewed from the extracellular side. The most important hemichannel residues (percentage of interaction \> 55%) interacting with abEC1.1 are highlighted. In panel **B**, different protomers (P1 to P6) of the hCx26 hemichannel are shown with different colors; labeled circles represent the position of the alpha carbon of residues shown in panel **A**; orange and blue residues represent the binding regions of the two scFv composing each diabody. Four N-T-L motifs are inscribed in an ellipse to indicate interaction of the corresponding hemichannel residues with either one (for P2 and P5) or both (for P1 and P4) binding diabodies. **(C,D)** Positions of all single protomer residues potentially involved in the interaction with the hemichannel (**C**, top view; **D**, side view); the EC1 loop is represented in red, the EC2 loop in light blue.](fphys-10-00392-g002){#F2}

![Detailed representation of the predicted interaction of abEC1.1 with the different protomers composing a hCx26 hemichannel. Panels **(A--D)** show four representative snapshots along the MD simulation highlighting the most important interactions; different protomers are represented according to the color code used in [Figure 2B](#F2){ref-type="fig"}. The antibody heavy chain (HC) and light chain (LC) are represented in red and cyan, respectively. Each protein is represented according to its realistic volume occupation in space. Critical residues are shown with atomistic detail.](fphys-10-00392-g003){#F3}

###### 

Sequence alignment of human connexin proteins in the regions where hCx26 is presumed to bind abEC1.1.

  Gene Name   Protein name   EC1 amino acids 54--58   EC2 amino acids 175--176
  ----------- -------------- ------------------------ --------------------------
  *GJB2*      hCx26          NTLQP                    PN
  *GJB6*      hCx30          NTLQP                    PN
  *GJB1*      hCx32          NTLQP                    PN
  *GJB4*      hCx30.3        NTKQP                    PH
  *GJD3*      hCx31.9        NTLQP                    PH
  *GJA8*      hCx50          NTQQP                    PN
  *GJA3*      hCx46          NTQQP                    PN
  *GJA10*     hCx62          NTRQP                    PN
  *GJB5*      hCx31.1        NTRQP                    PN
  *GJB3*      hCx31          NTKQP                    PN
  *GJA9*      hCx59          NTEQP                    PN
  *GJC2*      hCx47          NTRQP                    PH
  *GJA1*      hCx43          NTQQP                    PH
  *GJA5*      hCx40          DTIQP                    PH
  *GJD4*      hCx40.1        NTLQP                    TG
  *GJC1*      hCx45          NTEQP                    PH
  *GJD2*      hCx36          NTLQP                    IK
  *GJG3*      hCx30.2        HTQQP                    LG
  *CJB7*      hCx25          NSRQP                    PN
  *GJA4*      hCx37          NTAQP                    PY

Residue Thr177 is part of the putative binding interface (see P3-EC2 in

Table 2

) but contributes only with its main chain, therefore it was not included in this table.

Experimental Validation of Model Predictions by Patch Clamp in HeLa DH Transfectants
------------------------------------------------------------------------------------

To test these hypotheses, we performed a series of experiments in HeLa DH cells transiently transfected with the cDNAs encoding selected human connexins tagged with the Venus fluorescent protein at their C-terminus (see section "Materials and Methods"). The analysis was carried out on HeLa DH transfectants that generated reliable responses to a previously tested voltage clamp protocol ([@B73]) designed to elicit hemichannel currents upon depolarization followed by tail currents upon hyperpolarization.

In cells expressing hCx30 (encoded by *GJB6*) and hCx32 (*GJB1*), whole cell current recordings showed a major reduction of the elicited currents in the presence of the antibody (952 nM; [Figure 4A,B](#F4){ref-type="fig"}). Incubating hCx30 or hCx32 HeLa DH transfectants in Ca^2+^-free extracellular medium containing Lucifer Yellow (1 mM) promoted dye uptake, which was strongly reduced in cells that had been pre-incubated for 30 min with the antibody (952 nM; [Figure 4C](#F4){ref-type="fig"}).

![The abEC1.1 antibody inhibits hCx30 and hCx32 hemichannels in HeLa DH transfectants. **(A,B)** Whole cell currents elicited by voltage commands (top, black trace) recorded from HeLa DH cells transiently transfected with hCx30 **(A)** or hCx32 **(B)** and perfused with an extracellular solution containing 0.2 mM Ca^2+^ concentration. Shown are mean values (thick traces) ± s.e.m. (thin traces) for at least *n* = 3 cells in each data set. Total hemichannel currents were measured before (blue traces, control) and after (green traces) application of abEC1.1 by pressure at 952 nM for 15 min. Data were normalized to the mean value of the control response evoked by application of the depolarization step. Top insets show normalized outward currents measured immediately after the voltage commands to +40 mV **(A)** or +60 mV **(B)**. Asterisks indicate significance level between control condition and antibody application (^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001, paired *t*-test). **(C)** Dye uptake assays (see section "Materials and Methods"). Cells were bathed in a divalent-free extracellular medium (ECM) or ECM + 952 nM abEC1.1. Shown are representative fluorescence images of the same field of view before (*t*~0~) and after 30 min of incubation with 2 mM Lucifer Yellow (*t*~30~). These experiments were performed twice for each type of HeLa DH transfectants (Mock, hCx30, hCx32). Histogram shows mean values ± s.e.m. of the difference between *t*~30~ and *t*~0~ fluorescence intensity values measured in 50 cells for each condition (A.U., arbitrary units; ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001, Mann--Whitney *U* test). Scale bar = 20 μM.](fphys-10-00392-g004){#F4}

At this concentration, the antibody was significantly less effective on all other connexin hemichannels of the pool we tested ([Figure 5](#F5){ref-type="fig"}), namely hCx30.2/31.3 (*GJC3*), hCx30.3 (*GJB4*), hCx31(*GIB3*), hCx31.1 (*GJB5*), hCx37 (*GJA4*), hCx43 (*GJA1*), hCx45 (*GJC1*). [Figure 5B](#F5){ref-type="fig"} provides a quantitative summary of these results in histogram form: residual hemichannel conductance following antibody application was equal to 16.8% for hCx26 (data from [@B73]), 16% for hCx32, 25% for hCx30, 91% for hCx30.2/31.3, 82% for hCx30.3, 87% for hCx31, 73% for hCx31.1, 73% for hCx37, 73% for hCx43 and 98% for hCx45.

![Specificity of the abEC1.1 antibody for different connexin hemichannels expressed in HeLa DH cells. **(A)** Black traces at the top represent voltage commands applied under patch clamp conditions in order to elicit whole cell currents. Shown are mean values (thick traces) ± s.e.m. (thin traces) of currents recorded in control conditions (blue traces) and after (green traces) abEC1.1 application by pressure at 952 nM concentration from a glass micropipette for 15 min. All data were normalized to the mean value of current elicited by the depolarization step to +40 mV. The effect of the antibody was tested on at least *n* = 3 cells, for each different connexin isoform. HeLa DH transfectants were superfused into an extracellular solution with low calcium concentration (0.2 mM). Top insets show normalized outward currents measured immediately after the voltage commands to +40 mV. Data revealed no statistical difference between control condition and antibody application. **(B)** Histograms (mean ± s.e.m.) represent membrane conductance computed from data shown in panel **(A)** and normalized to current values measured before antibody application. Asterisks indicate significance level (^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001, ANOVA) for abEC1.1 effect on hemichannel currents measured in the indicated HeLa DH transfectants, taking hCx26 hemichannel currents in the presence of the antibody as reference.](fphys-10-00392-g005){#F5}

Pannexin 1 is an alternative mediator of intercellular signaling ([@B5]; [@B20]; [@B34]; [@B13]; [@B7]; [@B25]) with a pharmacology profile that overlaps partially that of connexin hemichannels ([@B19]; [@B32]). In HeLa-Panx1-YFP cells, which express no connexins ([@B75]), plasma membrane channels composed of pannexin 1 were not affected by abEC1.1 (applied at 952 nM concentration, [Figure 6A](#F6){ref-type="fig"}), but were blocked by known non-specific pannexin inhibitors such as probenecid, carbenoxolone (CBX), 4,4-Diisothiocyanatostilbene-2,2-disulfonic acid (DIDS) and Fast Green FCF ([Figure 6B,C](#F6){ref-type="fig"}). Altogether, these results indicate that abEC1.1 can discriminate between pannexin 1 channels and hemichannels composed of hCx26, hCx30 or hCx32.

![The abEC1.1 antibody does not affect human pannexin 1 (Panx1) hemichannel currents in HeLa-Panx1-YFP cells. Black traces at the top represent voltage protocols applied under patch clamp conditions to elicit whole cell currents in HeLa cells expressing Panx1. **(A)** Whole cell currents recorded in response to voltage steps from --80 to +120 mV before (control conditions) and after abEC1.1 antibody application at 952 nM for 15 min. **(B)** Inhibition of human Panx1 currents: shown are measurements of whole cell currents recorded in response to voltage protocol application after inhibitory compounds were delivered by pressure for 2 min (CBX, 50 μM) or 4 min (DIDS, Probenecid, Fast Green FCF, 100 μM). Results in panels **(A)** and **(B)** are representative of 4 to 8 experiments for each condition. **(C)** Histograms (mean ± s.e.m.) represent maximal outward and inward currents normalized to corresponding control values measured before antibody or pannexin inhibitor application. Asterisks indicate significance level relative to Control (^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001, ANOVA).](fphys-10-00392-g006){#F6}

Assay of Antibody *in vitro* Stability by Size Exclusion Chromatography (SEC)
-----------------------------------------------------------------------------

Aggregation of monoclonal antibodies into high molecular weight species is an irreversible process that is notorious for its detrimental effects on antibody efficiency and safety ([@B6]). SEC is a widespread method for stability monitoring due to its short run times and quantitative reproducibility ([@B33]). The peak-normalized chromatographic profiles (absorbance at 405 nm vs. retention time) in [Figure 7A](#F7){ref-type="fig"} indicate abEC1.1 undergoes minimal or no aggregation for up to 16 days at temperatures comprised between 4°C and 37°C. Some abEC1.1 aggregates become noticeable for samples held at 42°C for 16 days. [Figure 7B](#F7){ref-type="fig"} shows representative chromatographic profiles obtained from abEC1.1m, an antibody with the scFv domain of abEC1.1 fused in frame to a mouse Fc. A higher tendency to aggregate, signaled by the appearance of multiple peaks for abEC1.1m held at 42°C for 16 days, is evident at these rather extreme conditions. Altogether, these results confirm that abEC1.1 is a potential candidate protein biopharmaceutical.

![Peak-normalized SEC chromatographic profiles (absorbance vs. retention time) of antibodies maintained under different storage conditions. **(A)** abEC1.1; **(B)** abEC1.1m; see section "Materials and Methods" and Refs. therein.](fphys-10-00392-g007){#F7}

Discussion
==========

Anti-connexins Antibodies as Tools to Interfere With Hemichannel Function
-------------------------------------------------------------------------

A few monoclonal or polyclonal antibodies that recognize the extracellular domain of Cx43 have been generated ([@B48]; [@B35]; [@B64]; [@B3], [@B4]) and used in diverse contexts to address biological questions regarding gap junction assembly and hemichannel function \[reviewed in [@B58]\], as well as for the potential treatment of cancer and inflammatory states ([@B36]). Polyclonal "CELAb" antibodies raised in rabbits against a peptide corresponding to residues 42--53 in the EC1 region of hCx26 (VWGDEQADFVC), or another peptide corresponding to residues 172--184 in EC2 (AWPCPNTVDCFVSR), were used to detect Cx26 hemichannels in HeLa cells transfected with Cx26-eYFP, as well as to block dye uptake promoted by low Ca^2+^ conditions in both HeLa cells and CaCo-2/TC7 cells ([@B17]). The same antibodies detected connexin hemichannels also at the endolymphatic surface of the organ of Corti in mouse organotypic cochlear cultures ([@B2]; [@B45]). However, to our knowledge, no translational follow-up has been developed using CELAb antibodies.

Structural Determinants of abEC1.1-Hemichannel Interaction
----------------------------------------------------------

abEC1.1 is the first connexin-binding human-derived monoclonal antibody that was selected from a vast phage display library ([@B76]) using a bait peptide corresponding to residues 41-56 of EC1 in hCx26 ([@B55]). In the following, we will refer to hemichannel interactions with one of the two binding antibodies, keeping in mind that the pattern is symmetrical for the second antibody. Prior work allowed us to identify critical residues in the hemichannel-antibody binding interface, namely EC1 residues Asn54, Thr55 and Leu56, and antibody residues Tyr34, His55 and Trp104 ([@B73]). This work extends those results and suggests that two contiguous N-T-L motifs in P2-P3 accommodate the CDR3 of the antibody HC in a way that is reminiscent of hemichannel docking, owing in particular to the hydrophobic interactions of P2 and P3 Leu56 with Phe102 and Trp104 of the antibody. Likewise, P1 and P2 N-T-L motifs bind both the scaffold and, partially, the CDR2 loop of the antibody light chain, due to the formation of hydrogen bonds between antibody Arg183 and P1 Ans54, and to the interaction of antibody Tyr178 and Thr183 with Thr55 and Leu56 of P2. The conclusion based on this analysis is that the EC1 loop apex in all six protomers contributes to antibody binding ([Figure 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"} and [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). Residues Thr30, Ser32, Ser33 and Tyr34 in the CDR1 of the antibody HC reside between the EC1 of P3 and P4 and occupy a more external position relative to the center of the channel, so that also Gln57 and Pro58 in EC1 and Pro175 in EC2 are involved in the antibody-connexon interaction. Finally, the CDR2 of the antibody HC interacts with P3 only through His55, which finds an equilibrium position between the apical part of EC1 (Asn54) and EC2 (Pro175, Asn176 and the main chain of Thr177). Note that, apart from the EC2 Asp179, all other EC1 and EC2 residues, which are critical for hemichannel docking and formation of intercellular channels, mediate also hemichannel binding to the antibody.

###### 

Interaction probability of hCx26 residues with abEC1.1.

  Hemichannel amino acid   Interaction probability
  ------------------------ -------------------------
  **P1-EC1**               
  Asn54                    82%
  Thr55                    56%
  Leu56                    85%
  **P1-EC2**               
  Pro175                   29%
  **P2-EC1**               
  Cys53                    10%
  Asn54                    92%
  Thr55                    82%
  Leu56                    100%
  Gln57                    78%
  Pro58                    31%
  **P2-EC2**               
  Pro173                   2%
  Pro175                   68%
  Asn176                   21%
  Thr177                   4%
  Val178                   2%
  **P3-EC1**               
  Asn54                    63%
  Thr55                    7%
  Leu56                    100%
  Gln57                    65%
  Pro58                    7%
  **P3-EC2**               
  Trp172                   12%
  Pro173                   7%
  Pro175                   43%
  Asn176                   56%
  Thr177                   68%
  **P4-EC1**               
  Thr55                    2%
  Leu56                    85%
  Gln57                    90%
  Pro58                    73%
  **P4-EC2**               
  Pro175                   14%
  Asn176                   5%

At blocking concentrations, two antibodies bind simultaneously a single hCx26 hemichannel (

Xu et al., 2017

). Different hCx26 protomers (P1 to P6) contribute to the binding interface with different residues. One of the two antibodies binds protomers P1-P2-P3-P4; the second binds protomers P4-P5-P6-P1 with an identical interaction pattern. The interaction probability was computed as the time fraction the listed hCx26 residues were in close contact with the antibody during the MD simulation.

###### 

Interaction probability of abEC1.1 residues with the extracellular domain of the hCx26 hemichannel.

  Antibody amino acid      Interaction probability   Antibody amino acid      Interaction probability
  ------------------------ ------------------------- ------------------------ -------------------------
  **HC Constant Region**                             **LC Constant Region**   
  Ser27                    19%                       Tyr178                   80%
  Asn76                    14%                       Thr182                   98%
  Ser77                    5%                        Arg183                   93%
  Asn79                    2%                        Ala184                   58%
                                                     Thr185                   85%
  **HC-CDR1**                                        Gly186                   68%
  Gly28                    29%                       Ile187                   43%
  Phe29                    53%                       Pro188                   63%
  Thr30                    100%                      Asp189                   85%
  Ser32                    70%                                                
  Ser33                    98%                       **LC-CDR1**              
  Tyr34                    98%                       Ser160                   5%
  **HC-CDR2**                                        **LC-CDR2**              
  His55                    73%                       Gly179                   2%
                                                     Ser181                   37%
  **HC-CDR3**                                                                 
  Phe102                   78%                                                
  Ser103                   90%                                                
  Trp104                   100%                                               
  Arg105                   17%                                                

The interaction probability was computed as the time fraction the listed abEC1.1 residues were in close contact with extracellular domain of the hCx26 hemichannel during the MD simulation. HC, heavy chain; LC, light chain; CDR, complementarity determining region.

Together with sterical hindrance arguments, this analysis provides a mechanistic cue for the observed strong reduction of electrical conductance and dye uptake for hCx26 ([@B73]), hCx30 and hCx32 hemichannels (this work), which have 100% identical sequences in the predicted binding region (in hCx30 the amino acid corresponding to Thr177 is a Leu, but the interaction with the antibody is only mediated by the oxygen and nitrogen of the main chain).

Summarizing, the pattern of interaction is remarkably rich and the repeated N-T-L sequence binds different regions of the antibody. A single amino acid difference in a limited group of 8 protomer residues is sufficient to reduce significantly the antibody effects on all other types of hemichannels tested. Residues belonging to the hemichannel and the antibody which contribute most to the interaction are shown in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}, respectively.

Antibody Selection Based on Phage Display Library Screening: Potential and Caveats
----------------------------------------------------------------------------------

The atomistic model presented here, validated by patch clamp measurements, imply that it is possible to identify hemichannel blocking antibodies which are specific at least for different connexin subfamilies. However, our results also imply that screening antibody libraries against a simple bait peptide does not guarantee that the selected antibodies recognize the hemichannel surface exposed to the solvent. Indeed, it is well known that successful isolation of novel antibodies by phage display is critically limited by the presentation of a correctly folded antigen. The discovery of new and more selective antibodies capable of interfering with connexin hemichannels will undoubtedly benefit from improved methods targeting membrane proteins in their native conformation and optimized for whole cell biopanning ([@B37], [@B38]).

Concluding Remarks
==================

Given that abEC1.1 is stable *in vitro*, we consider the results presented here as potentially relevant for disorders caused by augmented hemichannel activity of hCx26 ([@B68]; [@B31]; [@B41]; [@B49]; [@B60]; [@B30]), hCx30 ([@B27]) and hCx32 ([@B1]; [@B43]), which include *Keratitis-ichthyosis-deafness syndrome* (OMIM 148210), *Hystrix-like ichthyosis with deafness* (OMIM 602540), *Ectodermal displasia 2, Clouston type* (OMIM 129500), and *Charcot-Marie-Tooth disease, X-linked dominant, 1* (OMIM 302800). *In vivo* experiments with relevant animal models will be key to test the therapeutic potential of this antibody.
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3D

:   three-dimensional

\[Ca^2+^\]

:   calcium ion concentration

Ca^2+^

:   calcium ion

CBX

:   carbenoxolone, 3β-Hydroxy-11-oxoolean-12-en-30-oic acid 3-hemisuccinat

CDR

:   complementarity determining regions

CTD

:   C-terminal domain

Cx

:   connexin

DIC

:   differential interference contrast

DIDS

:   4,4-Diisothiocyanatostilbene-2,2-disulfonic acid

DMEM

:   Dulbecco's modified Eagle's medium

EC1,2

:   extracellular loop 1, 2

ECS~NaCl~

:   sodium chloride-based extracellular solution

FBS

:   fetal bovine serum

Fc

:   fragment constant

HC

:   heavy chain

ICL

:   intracellular loop

ICS~KAsp~

:   potassium aspartate-based intracellular solution

IgG1

:   immunoglobulin G1

LC

:   light chain

MD

:   molecular dynamics

NTH

:   N-terminal helix

OD

:   optical density

ORF

:   open reading frame

P1-6

:   protomers 1 to 6 of a homomeric hCx26 hemichannel

PBS

:   phosphate-buffered saline

ScFv

:   single chain fragment variable

SEC

:   size exclusion chromatography

TEA-Cl

:   4 tetraethyl ammonium chloride

TM1-4

:   transmembrane helix 1 to 4

Wt

:   wild type

YFP

:   yellow fluorescent protein
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